Rockefeller Capital Management
AMLX icon

Rockefeller Capital Management’s Amylyx Pharmaceuticals AMLX Stock Holding History

Rockefeller Capital Management’s Portfolio AMLX Stock Details AMLX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$22.9K Hold
1,274
– – ﹤0.01% 3694
2026
Q1 		$17.7K Buy
1,274
+1,013
+388% +$14.2K ﹤0.01% 3757
2025
Q4 		$3.15K Buy
261
+256
+5,120% +$3.48K ﹤0.01% 4202
2025
Q3 		$68 Buy
+5
New +$47 ﹤0.01% 4386

Other funds holding AMLX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
CC
Commodore Capital New York $1.68B AUM 375.52% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
SVCM
Saturn V Capital Management Austin, Texas $697M AUM 628.57% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return

Rockefeller Capital Management's AMLX Position: Q2 2026 in Review

Rockefeller Capital Management held its Amylyx Pharmaceuticals (AMLX) position steady in Q2 2026 at 1,274 shares worth $22.9K. The position accounts for ﹤0.01% of the portfolio, ranked #3694.

Rockefeller Capital Management first reported a position in AMLX in Q3 2025 and has held it in 4 quarters since. 206 funds tracked by Wall St. Rank hold AMLX as of Q2 2026.

  • Rockefeller Capital Management held 1,274 shares of Amylyx Pharmaceuticals worth $22.9K as of Q2 2026.
  • Rockefeller Capital Management left its Amylyx Pharmaceuticals share count unchanged in Q2 2026.
  • Amylyx Pharmaceuticals made up ﹤0.01% of Rockefeller Capital Management's portfolio in Q2 2026, its #3694 holding.
  • Rockefeller Capital Management first reported a position in Amylyx Pharmaceuticals in Q3 2025 and has held it in 4 quarters since.
  • 206 funds tracked by Wall St. Rank held Amylyx Pharmaceuticals as of Q2 2026.

Based on Rockefeller Capital Management's 13F filing for Q2 2026, filed 13 Aug 2026.